Evofosamide | B1912

Evofosfamide (TH-302) is an anticancer agent that is a hypoxia-activated prodrug that is created by linking the hypoxia-seeking 2-nitroimidazole moiety to the cytotoxic bromo-isophosphoramide mustard (Br-IPM). When evofosfamide is delivered to hypoxic regions of tumors, the DNA cross-linking toxin, Br-IPM, is released leading to cell death.

Evofosfamide (TH-302) is an anticancer agent that is a hypoxia-activated prodrug that is created by linking the hypoxia-seeking 2-nitroimidazole moiety to the cytotoxic bromo-isophosphoramide mustard (Br-IPM). When evofosfamide is delivered to hypoxic regions of tumors, the DNA cross-linking toxin, Br-IPM, is released leading to cell death.

B1912 | Evofosamide DataSheet

Alternate Name/Synonyms: Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; TH302; TH-302

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 918633-87-1

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₉H₁₆Br₂N₅O₄P

Molecular Weight: 449.04

Cell-Permeable?: Yes

Purity: ≥98%

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: An anticancer agent

MDL Number: N/A

PubChem CID: 11984561

SMILES: CN1C(=CN=C1[N+](=O)[O-])COP(=O)(NCCBr)NCCBr

InChi: InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/h6H,2-5,7H2,1H3,(H2,13,14,19)

InChi Key: UGJWRPJDTDGERK-UHFFFAOYSA-N